AUSTEDO Drug Patent Profile

When do Austedo patents expire, and when can generic versions of Austedo launch?

Austedo is a drug marketed by Teva Branded Pharm and Teva and is included in two NDAs. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-two patent family members in thirty-four countries.

The generic ingredient in AUSTEDO is deutetrabenazine. One supplier is listed for this compound. Additional details are available on the deutetrabenazine profile page.

DrugPatentWatch^® Generic Entry Outlook for Austedo

Austedo was eligible for patent challenges on April 3, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 18, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AUSTEDO

International Patents:	132
US Patents:	14
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	4
Patent Applications:	22
Drug Prices:	Drug price information for AUSTEDO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AUSTEDO
What excipients (inactive ingredients) are in AUSTEDO?	AUSTEDO excipients list
DailyMed Link:	AUSTEDO at DailyMed

See drug prices for AUSTEDO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AUSTEDO

Constraining patent/regulatory exclusivity:

9,814,708*PED

NDA:

208082

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AUSTEDO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2/Phase 3
Vanderbilt University Medical Center	Phase 2/Phase 3
Fundacion Huntington Puerto Rico	Phase 1

See all AUSTEDO clinical trials

Paragraph IV (Patent) Challenges for AUSTEDO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUSTEDO	Tablets	deutetrabenazine	6 mg, 9 mg and 12 mg	208082	2	2021-04-05

US Patents and Regulatory Information for AUSTEDO

AUSTEDO is protected by fourteen US patents.

This potential generic entry date is based on patent 9,814,708.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-002	Feb 17, 2023		RX	Yes	No	11,446,291*PED				Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-003	Feb 17, 2023		RX	Yes	No	10,959,996*PED				Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-003	Apr 3, 2017		RX	Yes	Yes	11,357,772*PED				Y

International Patents for AUSTEDO

When does loss-of-exclusivity occur for AUSTEDO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

India

Japan

New Zealand

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AUSTEDO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	103876
Australia	2016229949
Australia	2021204740

Last updated: June 23, 2026

AUSTEDO Market Dynamics and Financial Trajectory (Deutetrabenazine)

AUSTEDO (deutetrabenazine) is a branded, FDA-approved treatment for chorea associated with Huntington’s disease (HD) and for tardive dyskinesia (TD). Its market growth has depended on (1) sustained prescription capture in both indications, (2) payer contracting and formulary placement, (3) competitive pressure from other symptomatic VMAT2 inhibitor options, and (4) the pace of conversion from initial treatment to longer-duration therapy in chronic neurological disease. Financial trajectory has typically been driven by unit growth, mix between TD and HD, and price net of rebates. Patent exclusivity and ongoing IP risk shape long-range pricing power, while FDA labeling expansion and dispensing behavior shape near-term demand.

How has AUSTEDO performed financially versus other VMAT2 inhibitors?

AUSTEDO competes within the VMAT2 inhibitor space that includes tetrabenazine products and deutetrabenazine’s direct alternative, including treatment paradigms that affect switching and continuation rates.

Key financial drivers

• Indication mix: TD generally drives broad, recurring demand; HD chorea is smaller but can be stickier as clinicians manage chronic motor symptoms.
• Payer economics: Net sales depend heavily on rebate level, specialty pharmacy channeling, prior authorization (PA), step edits, and specialty distribution fees.
• Dose and titration behavior: VMAT2 inhibitor markets can show ramp effects as patients titrate to effective maintenance dosing.
• Adherence in chronic disease: Neurology adherence patterns and persistence on therapy influence revenue durability.

Commercial reality for branded neuro drugs Branded neurologics usually show a pattern of:

• Initial uptake and conversion among neurologists/psychiatrists treating TD and HD chorea
• Periodic acceleration when formulary access improves or when outcomes data support earlier use
• A slowdown if payer restrictions tighten or if competitors improve access

What is the revenue and sales trajectory for AUSTEDO by indication (TD vs HD)?

AUSTEDO revenue trajectory typically tracks:

• TD prescription growth as awareness and payer access expand among patients exposed to dopamine-blocking agents.
• HD chorea growth as neurologist adoption increases in populations with symptomatic HD chorea.

Market dynamic profile

• TD: Typically larger addressable pool, but more controlled by plan rules due to budget impact.
• HD chorea: Higher clinical scrutiny but strong retention where patients tolerate therapy.

How do payer controls and specialty pharmacy dynamics shape AUSTEDO net sales?

Payer design determines the slope of net revenue more than list price.

Mechanisms that affect AUSTEDO sales

• Prior authorization and step edits: These can delay initiation, reduce first-fill volumes, and shift dosing timing.
• Formulary tiers and copay structures: Specialty tiering and copay assistance can materially change market share in chronic neuro.
• Specialty pharmacy distribution: Switching pharmacy benefits can reallocate shipments without reflecting real demand changes.
• Coverage policy revisions: Annual contract cycles often create abrupt changes in prescriptions and pull-through.

Net sales sensitivity

• Small changes in rebate rates or net-to-gross assumptions can change operating income disproportionately because branded volume declines often occur at the same time price pressure rises.

Which competitive forces most affect AUSTEDO market share?

Competitive forces are mainly driven by VMAT2 inhibitor alternatives, payer restrictions, and perceived tolerability.

Competition axes

• Product-level switching: Clinicians may switch between VMAT2 inhibitors based on side effect profiles, titration experience, and dosing convenience.
• Access constraints: If formulary inclusion shifts, prescriber behavior follows coverage.
• Clinical protocol and safety monitoring: VMAT2 inhibitors require QT and depression risk management considerations, impacting treatment pathways.

Outcome for AUSTEDO Market share tends to be strongest where AUSTEDO is the preferred VMAT2 inhibitor under payer policy and where clinicians find it easier to manage long-term dosing.

When does AUSTEDO lose patent exclusivity and how does that affect revenue risk?

For branded revenue protection, exclusivity and patent expiration create the main forward-looking revenue downside from generic entry and price compression.

Revenue risk channels

1. Near-term IP challenges can foreshadow price declines even before loss of exclusivity, depending on settlement posture.
2. Orange Book patent expirations determine when ANDA filers can be approved (for non-biologic drugs).
3. Formulation and method-of-use patents can slow “workalike” competition even after base compound protection ends, depending on claim scope and launch design.

Because this request is focused on market dynamics and financial trajectory, the actionable takeaway is that AUSTEDO’s long-term topline visibility depends on the remaining time to:

• expiration of key Orange Book-listed patents, and
• whether challengers have filed for FDA approval ahead of expiration (Paragraph IV framework).

What is the Orange Book status of AUSTEDO and what does it imply for future generics?

AUSTEDO is a small-molecule pharmaceutical (deutetrabenazine), so FDA exclusivity and Orange Book patent listings govern generic entry timing.

Commercial implication

• If the Orange Book estate has multiple expiring patents layered across claims (drug substance, composition, method-of-use), generic entry may occur in phases.
• Early-stage generics can trigger immediate reimbursement pressure if payers treat them as therapeutically equivalent.
• If method-of-use claims remain enforceable, payers may be forced to maintain coverage restrictions until full clearance.

Do Paragraph IV filings exist for AUSTEDO and what is the litigation timeline risk?

For branded small molecules, Paragraph IV challenges and district court litigation can determine:

• whether entry is delayed by injunctions,
• whether a settlement triggers “at-risk” launches,
• and whether generic competitors coordinate timing based on enforceable claim scope.

Financial trajectory linkage

• Positive litigation and delayed challenges can extend premium pricing.
• Active challenges increase volatility in forecast models and can influence payer negotiations.

How strong is the patent estate for AUSTEDO in TD and HD chorea?

Patent strength matters because it constrains the ability to substitute competing products at similar dosing.

Estate strength factors

• Number of listed patents (and the distribution of expiration dates)
• Claim coverage breadth: whether patents cover dosing regimens, formulations, or use in specific indications
• Infringement durability: whether generic launch design can avoid claims via labeling or manufacturing differences

What formulation and dosing changes can protect AUSTEDO from full substitution?

In small-molecule chronic therapy markets, lifecycle management often includes:

• dose-titration guidance linked to safety tolerability,
• formulation improvements that affect bioavailability or stability,
• and labeling expansion that creates incremental protectable use.

Even when compound-level exclusivity ends, formulation or method-of-use claims can delay interchangeable substitution if payers require covered labeling.

What generic entry risks exist for AUSTEDO and what launch scenarios are most likely?

Generic competition risk usually takes one of two shapes:

Scenario A: Full substitution after key expirations

• Generics launch at or soon after patent expiration.
• Payors broaden coverage and reduce copays, leading to rapid share shift.
• AUSTEDO net price compresses as rebate pressure increases.

Scenario B: Partial substitution with claim-driven launch limits

• Generics launch with label carve-outs or limited claim coverage.
• Payors may maintain PA policies and restrict switching.
• Share loss is slower, with price compression spread over time.

How does AUSTEDO compare with tetrabenazine and other VMAT2 options on access and economics?

Comparison outcomes are often payer-driven rather than pure clinical superiority.

Access and economics comparisons

• Products that are easier to cover without PA or that align to payer preferred drug lists usually win faster.
• If a competitor offers a more favorable net price structure or lower formulary barriers, market share can shift quickly.

Clinical workflow effects

• Neurologists and psychiatrists often prioritize regimens that reduce monitoring friction and titration complexity.
• Where AUSTEDO is positioned as tolerable and manageable, switching barriers can persist even when generic alternatives exist for other VMAT2 drugs.

What FDA regulatory status and label scope drive long-term demand for AUSTEDO?

AUSTEDO’s commercial runway depends on label fit for clinical practice:

• TD and HD chorea are chronic, ongoing therapy areas.
• Any label expansion affects eligible patient pools.
• Safety profile perception influences long-run persistence and refill patterns in specialty settings.

How do manufacturing and supply-chain factors affect AUSTEDO continuity and sales?

Even when demand is stable, supply events can damage revenue trajectories.

Supply-chain risk factors

• Specialty drug manufacturing constraints and batch release timing
• Distribution lead times to specialty pharmacies
• Shortages that can force pauses in therapy and harm persistence

What is the commercialization history of AUSTEDO and why does it matter for market dynamics?

Commercial history influences:

• where physicians treat today (site of care)
• how formularies evolved
• which payer networks absorbed the product early

AUSTEDO’s uptake typically reflects neurologist and psychiatrist onboarding plus specialty pharmacy pull-through. Over time, the market stabilizes where coverage is consistent and PA criteria are satisfied.

Key market dynamics timeline: what to monitor next

Because financial trajectory is forward-looking, the practical monitoring set is:

1. Payer policy changes for TD and HD chorea coverage and step-edit enforcement
2. Formulary wins/losses in top commercial plans
3. Specialty pharmacy contracting shifts and channel metrics
4. Any Paragraph IV developments that could trigger forecast revisions
5. Patent expiration schedule for key Orange Book-listed claims

Key Takeaways

• AUSTEDO’s market growth has been driven by TD and HD chorea demand, but net revenue is highly sensitive to payer rebates, PA rules, and specialty pharmacy contracting.
• Longer-term financial trajectory depends on how the remaining patent and exclusivity landscape limits generic and therapeutically equivalent substitution, including whether method-of-use or formulation claims constrain launch design.
• The most material near-to-midterm revenue risks typically come from Paragraph IV-driven anticipation of price compression and from payer tightening around branded VMAT2 inhibitors.
• The market is structured so that access and persistence in chronic neurological disease shape topline more than list pricing.

FAQs

1. How quickly can AUSTEDO prescriptions convert after formulary approval changes in TD?
2. What net-to-gross assumptions matter most when modeling AUSTEDO profitability?
3. How do PA criteria for AUSTEDO differ between TD and Huntington’s chorea, and how does that affect patient starts?
4. What launch design strategies do generic challengers use to reduce Orange Book infringement risk for AUSTEDO?
5. How does persistence (months on therapy) for VMAT2 inhibitors influence AUSTEDO revenue volatility?

References

No sources were provided in the prompt.

DrugChatter Q&A for AUSTEDO

Austedo xr choreahd medication costts?
Austedo xr treatment pricing for tardive dyskinesia?
Austedo vs valbenazine price?
Austedo xr generic available?
Austedo spain is it registered or not?